Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.

Abstract: A computer system, method, or computer-readable medium controls a potentially unacceptable software component intended for a software repository. A pre-defined application or repository policy associated with the repository or application pre-defines risks and, for each of the risks, an action to take for the risk. The action can be a pass action or a does-not-pass action, which are pre-defined programmatic steps also defined in the policy. When the component is not new to the repository or the application, the component is passed through for the usual handling. When the component is new, risks are determined that match the software component; for risks which match, the actions are taken as defined in the pre-defined policy. The pass action can include adding the software component to the software repository. The does-not-pass action is followed for a component that does not pass as a potentially unacceptable software component.

Abstract: A container for an article includes a series of walls including a top wall that cooperate to define an interior of the container. A brace assembly is positioned toward an upper end defined by the interior of the container, and includes a brace member that is positioned below the top wall of the container and that defines opposite ends, each of which is located adjacent one of a pair of opposite sidewalls of the container. The brace assembly includes a carrier, which may be formed of a series of corrugated panels, and the brace member may be secured to a hinged brace member mounting panel such that the brace member is suspended above an upper surface of an article within the container interior and below the top wall of the container.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: Enzymes for depolymerizing lignin. The enzymes include dehydrogenases, ?-etherases, and glutathione lyases. The dehydrogenases can comprise one or more or LigD, LigO, LigN, and LigL. The ?-etherases can comprise one or more of LigE, LigF, LigP, and BaeA. The glutathione lyases can comprise any one or more of LigG and a number of non-stereospecific, optionally recombinant glutathione lyases derived from Sphingobium sp. SYK-6, Novosphingobium aromaticivorans, Escherichia coli, Streptococcus sanguinis, Phanerochaete chrysosporium, and other microorganisms. The enzymes can be combined in compositions and/or used in methods of processing lignin or other aromatic compounds in vitro.

Abstract: An electronic device, computer-readable medium, and method executed by the electronic device including the steps of activating at least one camera of the electronic device, receiving one or more images of an object comprising at least one graphic printed thereon or embedded therein via the at least one camera, recognizing the at least one graphic within at least one image in the one or more images, determining a pre-programmed output in one or more pre-programmed outputs based at least in part on the recognized at least one graphic, and transmitting the pre-programmed output via one or more of at least one speaker of the electronic device or the at least one display of the electronic device.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The invention is directed to p-coumaroyl-CoA:monolignol transferase enzymes, nucleic acids encoding p-coumaroyl-CoA:monolignol transferase enzymes, and inhibitory nucleic acids adapted to inhibit the expression and/or translation of p-coumaroyl-CoA:monolignol transferase RNA; expression cassettes, plant cells, and plants that have or encode such nucleic acids and enzymes; and methods of making and using such nucleic acids, enzymes, expression cassettes, cells, and plants.

Abstract: The invention relates to feruloyl-CoA:monolignol transferase enzymes and nucleic acids encoding the feruloyl-CoA:monolignol transferase enzymes. The enzymes and/or the nucleic acids enable incorporation of monolignol ferulates into the lignin of plants. The monolignol ferulates include, for example, p-coumaryl ferulate, coniferyl ferulate, and/or sinapyl ferulate.

Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

Abstract: A computer system, method, or non-transitory computer-readable medium provides an authoritative name source for files within an ecosystem. Files in the ecosystem which have identical contends and similar contents to each other are merged into the same supercluster, to capture possibly incremental changes to the files over time in one of the superclusters. For each supercluster which has files with identical and similar contents, the supercluster is broken down into package clusters, based on packages to which the files belong, each of the package clusters has the files from a same package. The package cluster which has most change frequency across versions, is identified as the authoritative package. The authoritative name for the files is resolved, based on the authoritative packages that are determined, across the plurality of superclusters which have files with identical and similar contents, and the authoritative name is generated. Any authoritative name collision is resolved.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: A computer system, method, or non-transitory computer-readable medium provides an authoritative name source for files within an ecosystem. Files in the ecosystem which have identical contends and similar contents to each other are merged into the same supercluster, to capture possibly incremental changes to the files over time in one of the superclusters. For each supercluster which has files with identical and similar contents, the supercluster is broken down into package clusters, based on packages to which the files belong, each of the package clusters has the files from a same package. The package cluster which has most change frequency across versions, is identified as the authoritative package. The authoritative name for the files is resolved, based on the authoritative packages that are determined, across the plurality of superclusters which have files with identical and similar contents, and the authoritative name is generated. Any authoritative name collision is resolved.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.